Sebastian W Nielsen1, Christina H Ruhlmann2,3, Lise Eckhoff3, Dorthe Brønnum4, Jørn Herrstedt5,6, Susanne O Dalton6,7. 1. Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Vestermarksvej 9, 4000, Roskilde, Denmark. sewn@regionsjaelland.dk. 2. Department of Clinical Research, University of Southern Denmark, 5000, Odense C, Denmark. 3. Department of Oncology R, Odense University Hospital, 5000, Odense C, Denmark. 4. Centre for Clinical Research, North Denmark Regional Hospital, 9800, Hjoerring, Denmark. 5. Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Vestermarksvej 9, 4000, Roskilde, Denmark. 6. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 1165, Copenhagen, Denmark. 7. Survivorship and Inequality in Cancer, Danish Cancer Society Research Center, 2100, Copenhagen, Denmark.
Abstract
PURPOSE: Patients with cancer are using cannabis for self-treatment. The reasons, experienced effects, and prevalence of use are unknown in the European general oncological population. METHODS: Adult patients with cancer attending outpatient oncology clinics were invited to participate in a cross-sectional survey. The questionnaire consisted of sociodemographic questions, validated scales on quality of life, neuropathy, anxiety and depression as well as questions regarding use of cannabis. RESULTS: The overall response rate was 83% (2839 patients) and 13% of patients were using or had used cannabis during their treatment. Rate of use was higher in smokers (19% vs 11%, p adjusted 0.002), in patients in active cancer treatment (14% vs 10%, p adjusted = 0.02), and in patients with depression (19% vs 11%, adjusted p = 0.002). Cannabis use was also correlated with lower quality of life (EORTC C30 SumScore mean diff. = - 7.61, 95% CI = [- 9.69; - 5.53]). In total, 77% of users experienced at least one positive effect of cannabis, 18% experienced no effect, and 5% experienced other effects. At least one side effect was experienced by 33% of users. Management of pain and nausea were the primary reasons for initiating cannabis use (39% for both). Less nausea and better sleep were the most common effects experienced (26% for both). Oils for oral use were the most common route of administration (88%). CONCLUSION: Cannabis use among patients with cancer is prevalent and correlated with worse quality of life. Patients report using cannabis for symptom management and many experience relief of their symptoms. However, one third of patients experienced side effects.
PURPOSE: Patients with cancer are using cannabis for self-treatment. The reasons, experienced effects, and prevalence of use are unknown in the European general oncological population. METHODS: Adult patients with cancer attending outpatient oncology clinics were invited to participate in a cross-sectional survey. The questionnaire consisted of sociodemographic questions, validated scales on quality of life, neuropathy, anxiety and depression as well as questions regarding use of cannabis. RESULTS: The overall response rate was 83% (2839 patients) and 13% of patients were using or had used cannabis during their treatment. Rate of use was higher in smokers (19% vs 11%, p adjusted 0.002), in patients in active cancer treatment (14% vs 10%, p adjusted = 0.02), and in patients with depression (19% vs 11%, adjusted p = 0.002). Cannabis use was also correlated with lower quality of life (EORTC C30 SumScore mean diff. = - 7.61, 95% CI = [- 9.69; - 5.53]). In total, 77% of users experienced at least one positive effect of cannabis, 18% experienced no effect, and 5% experienced other effects. At least one side effect was experienced by 33% of users. Management of pain and nausea were the primary reasons for initiating cannabis use (39% for both). Less nausea and better sleep were the most common effects experienced (26% for both). Oils for oral use were the most common route of administration (88%). CONCLUSION: Cannabis use among patients with cancer is prevalent and correlated with worse quality of life. Patients report using cannabis for symptom management and many experience relief of their symptoms. However, one third of patients experienced side effects.
Authors: Ilana M Braun; Traci M Blonquist; Eric G Campbell; Manan M Nayak; Dragana Bolcic-Jankovic; Alexi A Wright Journal: J Pain Symptom Manage Date: 2019-02-19 Impact factor: 3.612
Authors: F Roila; A Molassiotis; J Herrstedt; M Aapro; R J Gralla; E Bruera; R A Clark-Snow; L L Dupuis; L H Einhorn; P Feyer; P J Hesketh; K Jordan; I Olver; B L Rapoport; J Roscoe; C H Ruhlmann; D Walsh; D Warr; M van der Wetering Journal: Ann Oncol Date: 2016-09 Impact factor: 32.976
Authors: Emily J Cox; Neha Maharao; Gabriela Patilea-Vrana; Jashvant D Unadkat; Allan E Rettie; Jeannine S McCune; Mary F Paine Journal: Pharmacol Ther Date: 2019-05-07 Impact factor: 12.310
Authors: Amar H Kelkar; Nichole A Smith; Annia Martial; Harsha Moole; Michael D Tarantino; Jonathan C Roberts Journal: N Engl J Med Date: 2018-09-27 Impact factor: 91.245
Authors: Dawn L Hershman; Christina Lacchetti; Robert H Dworkin; Ellen M Lavoie Smith; Jonathan Bleeker; Guido Cavaletti; Cynthia Chauhan; Patrick Gavin; Antoinette Lavino; Maryam B Lustberg; Judith Paice; Bryan Schneider; Mary Lou Smith; Tom Smith; Shelby Terstriep; Nina Wagner-Johnston; Kate Bak; Charles L Loprinzi Journal: J Clin Oncol Date: 2014-04-14 Impact factor: 44.544
Authors: K Martell; A Fairchild; B LeGerrier; R Sinha; S Baker; H Liu; A Ghose; I A Olivotto; M Kerba Journal: Curr Oncol Date: 2018-06-28 Impact factor: 3.677
Authors: Steven A Pergam; Maresa C Woodfield; Christine M Lee; Guang-Shing Cheng; Kelsey K Baker; Sara R Marquis; Jesse R Fann Journal: Cancer Date: 2017-09-25 Impact factor: 6.860
Authors: Sebastian W Nielsen; Simone Dyring Hasselsteen; Helena Sylow Heilmann Dominiak; Dejan Labudovic; Lars Reiter; Susanne Oksbjerg Dalton; Jørn Herrstedt Journal: Support Care Cancer Date: 2022-08-06 Impact factor: 3.359